Published in Thromb Haemost on September 30, 2010
Risk factors for venous thromboembolism of total hip arthroplasty and total knee arthroplasty: a systematic review of evidences in ten years. BMC Musculoskelet Disord (2015) 0.89
Interrupting anticoagulation in patients with nonvalvular atrial fibrillation. P T (2014) 0.80
Oral factor Xa inhibitors for the long-term management of ACS. Nat Rev Cardiol (2012) 0.77
New anticoagulants - promising and failed developments. Br J Pharmacol (2012) 0.77
Inhibitors of propagation of coagulation: factors V and X. Br J Clin Pharmacol (2011) 0.76
Improve the results of phase II trials of thromboprophylaxis with the new oral anticoagulant drugs. Thromb Haemost (2010) 0.75
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med (2015) 10.86
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013) 8.74
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med (2008) 6.32
Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med (2010) 5.79
American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol (2007) 5.36
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med (2012) 5.25
Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med (2006) 5.18
Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med (2003) 5.02
Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. Chest (2006) 4.77
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med (2004) 4.52
Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med (2002) 3.96
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation (2004) 3.83
TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet (2012) 3.46
Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med (2013) 3.40
Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol (2008) 2.71
Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 2.50
Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med (2004) 2.34
Continued sports activity, using a pain-monitoring model, during rehabilitation in patients with Achilles tendinopathy: a randomized controlled study. Am J Sports Med (2007) 2.31
A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med (2010) 2.31
Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation (2012) 2.16
A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf (2007) 2.10
Acute achilles tendon rupture: a randomized, controlled study comparing surgical and nonsurgical treatments using validated outcome measures. Am J Sports Med (2010) 2.07
Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med (2006) 1.88
Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost (2009) 1.76
Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension (2011) 1.69
Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest (2010) 1.67
Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med (2005) 1.64
Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost (2008) 1.64
Dynamic reprogramming of chromatin accessibility during Drosophila embryo development. Genome Biol (2011) 1.61
The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich) (2011) 1.58
Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol (2005) 1.58
To share or not to share: a randomized trial of consent for data sharing in genome research. Genet Med (2011) 1.52
Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thromb Res (2006) 1.48
The Achilles tendon Total Rupture Score (ATRS): development and validation. Am J Sports Med (2006) 1.46
Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism? Br J Haematol (2009) 1.46
Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich) (2011) 1.44
Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiology. Thromb Haemost (2002) 1.44
Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood (2005) 1.43
A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions. Am Heart J (2006) 1.41
Dabigatran etexilate. Nat Rev Drug Discov (2008) 1.41
Endoscopic transventricular selective amygdalohippocampectomy: cadaveric demonstration of a new operative approach. World Neurosurg (2012) 1.40
Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery. Clin Pharmacokinet (2008) 1.39
Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost (2010) 1.39
Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost (2005) 1.27
The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines. Can J Cardiol (2011) 1.25
Antiretroviral resistance and high-risk transmission behavior among HIV-positive patients in clinical care. AIDS (2004) 1.23
International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J (2011) 1.20
Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. Thromb Haemost (2005) 1.19
PDX-1 acts as a potential molecular target for treatment of human pancreatic cancer. Pancreas (2008) 1.17
Major functional deficits persist 2 years after acute Achilles tendon rupture. Knee Surg Sports Traumatol Arthrosc (2011) 1.15
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost (2010) 1.14
Roles of cyclophilins in cancers and other organ systems. World J Surg (2005) 1.14
Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol (2006) 1.14
Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension (2012) 1.14
Contraceptive use among Canadian women of reproductive age: results of a national survey. J Obstet Gynaecol Can (2009) 1.13
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol (2006) 1.12
Prevalence and correlates of erectile dysfunction (ED) and treatment seeking for ED in Asian Men: the Asian Men's Attitudes to Life Events and Sexuality (MALES) study. J Sex Med (2007) 1.09
Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis (2003) 1.08
Fondaparinux, the first selective factor Xa inhibitor. Curr Opin Hematol (2003) 1.06
Kinematics and laxity of the knee joint after anterior cruciate ligament reconstruction: pre- and postoperative radiostereometric studies. Am J Sports Med (2002) 1.05
HIV drug resistance and HIV transmission risk behaviors among active injection drug users. J Acquir Immune Defic Syndr (2005) 1.05
Traffic flow in the operating room: an explorative and descriptive study on air quality during orthopedic trauma implant surgery. Am J Infect Control (2012) 1.04
Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail (2013) 1.04
Longitudinal patterns of offending during the transition to adulthood in youth from the mental health system. J Behav Health Serv Res (2004) 1.03
Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). Am Heart J (2008) 1.02
A new measurement of heel-rise endurance with the ability to detect functional deficits in patients with Achilles tendon rupture. Knee Surg Sports Traumatol Arthrosc (2009) 1.01
Stable surgical repair with accelerated rehabilitation versus nonsurgical treatment for acute Achilles tendon ruptures: a randomized controlled study. Am J Sports Med (2013) 1.01
Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol (2006) 1.01
Intra-abdominal fat predicts survival in pancreatic cancer. J Gastrointest Surg (2010) 1.00
Surgical management of valvular heart disease 2004. Can J Cardiol (2004) 0.99
Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected]. Int Orthop (2011) 0.98
Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model. Blood (2010) 0.97
Mind-body therapies in integrative oncology. Curr Treat Options Oncol (2010) 0.97
Cell-specific cytotoxicity of human pancreatic adenocarcinoma cells using rat insulin promoter thymidine kinase-directed gene therapy. World J Surg (2004) 0.96
Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. Drug Saf (2009) 0.96
Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med (2007) 0.95
Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. J Clin Hypertens (Greenwich) (2012) 0.95
PDX-1 expression is associated with islet proliferation in vitro and in vivo. J Surg Res (2007) 0.95
Roles of thymosins in cancers and other organ systems. World J Surg (2005) 0.94
PDX-1: demonstration of oncogenic properties in pancreatic cancer. Cancer (2010) 0.94
Predictors of adverse outcome among patients with hypertension and coronary artery disease. J Am Coll Cardiol (2006) 0.94
The impact of anogenital warts on health-related quality of life: a 6-month prospective study. Sex Transm Dis (2011) 0.94
Biodegradable and metallic interference screws in anterior cruciate ligament reconstruction surgery using hamstring tendon grafts: prospective randomized study of radiographic results and clinical outcome. Am J Sports Med (2006) 0.93